Three-dimensional organoid culture using the CellRaft microwell technology
Award amount
$1,233,851Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CELL MICROSYSTEMS INC
- Proposal award date
- 2020-08-01
- Contract end date
- 2022-07-31
- UEI
- G51EN7YDH7F3
- Solicitation number
- PA19-272
- Topic code
- R
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Rapid identification and selection of functional antigen-specific monoclonalantibodies by FcGR-enabled screening on CellRaft Arrays in the CellRaft AIRSystem
- Rapid identification and selection of functional antigen-specific monoclonal antibodies by FcGR-enabled screening on CytoSort Arrays in the CellRaft AIR System
- Improving iPSC reprogramming and CRISPR gene editing workflows and efficacy using CellRaft technology
- THE THE PURPOSE OF THE PHASE II PROGRAM IS TO FOCUS ON DEVELOPING A T-CELL ACTIVATION PROTOCOL CONSISTENT WITH REPORTERCELL VIABILITY, DEVELOPING A PR
- Three-dimensional organoid culture using the CellRaft microwell technology
Research funding history
19 SBIR/STTR records share this UEI (2013–2023). Reported award amounts total $15,051,342. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services